These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35442227)

  • 1. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease.
    Yossef L; Wright M; Benedict J; Morris GA; McNicol M; Boyle B; Dotson JL; Michel HK; Maltz RM
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):59-63. PubMed ID: 35442227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey.
    Maltz RM; McClinchie MG; Boyle BM; McNicol M; Morris GA; Crawford EC; Moses J; Kim SC
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):616-621. PubMed ID: 36827968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B; Dignaß A; Schreiber S
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
    Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group.
    Dipasquale V; Martinelli M; Aloi M; Accomando S; Alvisi P; Arrigo S; Banzato C; Bramuzzo M; Cananzi M; Corpino M; Di Mari C; Di Nardo G; Dilillo A; Dodaro N; Felici E; Gatti S; Graziano F; Illiceto MT; Norsa L; Opramolla A; Pastore M; Pavanello PM; Romeo E; Scarallo L; Strisciuglio C; Zuin G; Romano C
    Paediatr Drugs; 2022 Jan; 24(1):57-62. PubMed ID: 34914084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
    Danese S; Fiorino G
    Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
    Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
    J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
    [No Abstract]   [Full Text] [Related]  

  • 17. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
    Martínez-Feito A; Bravo-Gallego LY; Hernández-Breijo B; Diez J; García-Ramirez L; Jaquotot M; Plasencia-Rodríguez C; Nozal P; Mezcua A; Martín-Arranz MD; Pascual-Salcedo D
    Sci Rep; 2020 Oct; 10(1):17099. PubMed ID: 33051546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.